Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite presented as a sterile solution for subcutaneous use. It is employed to treat rheumatoid arthritis, psoriasis, and certain cancers such as acute lymphoblastic leukemia in adult patients.

GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methofill, an antimetabolite DMARD, is used in several disease pathways where cell proliferation and inflammation are central. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: improves skin lesions and decreases plaque formation. - Acute lymphoblastic leukemia: interferes with malignant cell replication and supports remission induction.

Methofill may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral ulceration or mucositis. - Elevated liver enzymes. - Mild leukopenia or neutropenia. - Skin rash or itching.

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis. - Pulmonary toxicity, including interstitial pneumonitis. - Significant bone‑marrow suppression leading to anemia or severe infection. - Renal impairment or acute kidney injury. - Rare hypersensitivity reactions such as Stevens‑Johnson syndrome. - Teratogenic effects with potential fetal malformations.

Before initiating Methofill, clinicians should assess baseline organ function and counsel patients on potential risks. - Liver monitoring: perform baseline and periodic liver function tests. - Hematologic monitoring: check complete blood counts regularly. - Renal function: adjust dose in patients with impaired clearance. - Pregnancy: avoid use in pregnant or nursing women; discuss contraception. - Vaccinations: postpone live vaccines while on therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Penicillins and other bactericidal antibiotics: may enhance myelosuppression. - Live vaccines: heightened risk of severe infection.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics: may increase hematologic toxicity. - Proton pump inhibitors: possible alteration of methotrexate clearance. - Trimethoprim‑sulfamethoxazole: may augment bone‑marrow suppression. - Azathioprine or other immunosuppressants: additive immunosuppression risk.